ATI RN
ATI Pharmacology Proctored Exam
1. A healthcare provider is preparing to administer an Opioid agonist to a client who has acute pain. Which of the following complications should the provider monitor?
- A. Urinary retention
- B. Tachypnea
- C. Hypertension
- D. Irritating cough
Correct answer: A
Rationale: The correct answer is urinary retention. Opioid agonists like morphine can suppress the awareness of bladder fullness, leading to urinary retention. This complication can result in significant discomfort and potential urinary tract issues if not promptly addressed. Tachypnea (increased respiratory rate) is a common side effect of opioids but is not a specific complication related to urinary retention. Hypertension is not typically associated with opioid agonists and is more commonly seen with opioid antagonists. An irritating cough is not a known complication of opioid agonists and is not directly related to the effect opioids have on the urinary system.
2. A client has a new prescription for rituximab. Which of the following findings should the nurse instruct the client to report?
- A. Dizziness
- B. Fever
- C. Urinary frequency
- D. Dry mouth
Correct answer: B
Rationale: The nurse should instruct the client to report fever. Fever can be an indication of an infection, a potential complication of rituximab therapy. Monitoring and reporting fever promptly can help in early intervention to prevent further complications. Dizziness, urinary frequency, and dry mouth are not typically associated with rituximab therapy and are less likely to be directly related to the medication. Therefore, they are not the priority findings to report in this scenario.
3. A client has a new prescription for radioactive iodine to treat Hyperthyroidism. Which of the following instructions should the nurse include?
- A. Expect a metallic taste in the mouth.
- B. Avoid contact with pregnant women for 1 week.
- C. Administer iodine solution using a straw.
- D. Take thyroid replacement medication for 3 weeks after treatment.
Correct answer: B
Rationale: When a client undergoes radioactive iodine treatment for hyperthyroidism, they can emit radiation for a short time. To prevent radiation exposure to others, especially pregnant women, infants, and small children, clients should avoid close contact for about 1 week following therapy. This precaution is essential to protect vulnerable individuals from potential harm. Choice A is incorrect because a metallic taste in the mouth is not a common side effect of radioactive iodine treatment. Choice C is incorrect because administering iodine solution using a straw is not a standard practice in this treatment. Choice D is incorrect because taking thyroid replacement medication for 3 weeks after treatment is not a typical instruction associated with radioactive iodine therapy for hyperthyroidism.
4. A client has a new prescription for Phenelzine for the treatment of depression. Which of the following indicates that the client has developed an adverse effect of this medication?
- A. Orthostatic hypotension
- B. Hearing loss
- C. Gastrointestinal bleeding
- D. Weight loss
Correct answer: A
Rationale: Orthostatic hypotension is a known adverse effect of MAOIs, such as Phenelzine. It is characterized by a drop in blood pressure upon standing, which can lead to dizziness or fainting. Monitoring for orthostatic hypotension is crucial when administering MAOIs to prevent potential complications. Hearing loss (Choice B) is not a typical adverse effect associated with Phenelzine. Gastrointestinal bleeding (Choice C) is more commonly linked to NSAIDs or anticoagulants. Weight loss (Choice D) is not a typical adverse effect of Phenelzine and is more likely related to other factors such as appetite changes or metabolic issues.
5. A drug ending in the suffix (navir) is considered a ______.
- A. Antidepressant
- B. Protease inhibitor
- C. Beta antagonist
- D. H antagonist
Correct answer: B
Rationale: When a drug name ends in the suffix -navir, it indicates that the drug is a protease inhibitor. Protease inhibitors are commonly used in antiviral therapy to treat infections by inhibiting viral replication. Therefore, the correct answer is B: Protease inhibitor.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access